| |
| |
|
| Insider
Information: |
Eisele Jeffrey |
| Relationship: |
Chief Development Offi... |
| City: |
Waltham |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
57,208 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,511,431 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
57,208 |
|
|
| Total
Value |
$2,511,431 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Apellis Pharmaceuticals Inc |
APLS |
Chief Development Offi... |
2024-01-30 |
57,208 |
2020-12-23 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2024-01-30 |
4 |
AS |
$65.53 |
$63,630 |
D/D |
(971) |
57,208 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2024-01-29 |
4 |
AS |
$64.14 |
$17,895 |
D/D |
(279) |
58,179 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2024-01-23 |
4 |
AS |
$63.69 |
$469,905 |
D/D |
(7,378) |
58,458 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2024-01-22 |
4 |
S |
$65.00 |
$104,449 |
D/D |
(1,607) |
65,836 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2024-01-17 |
4 |
AS |
$65.58 |
$341,475 |
D/D |
(5,207) |
67,443 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
19,508 |
73,088 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2024-01-16 |
4 |
S |
$66.81 |
$29,262 |
D/D |
(438) |
72,650 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2023-12-27 |
4 |
AS |
$60.23 |
$14,154 |
D/D |
(235) |
53,580 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2023-12-26 |
4 |
AS |
$57.86 |
$3,935 |
D/D |
(68) |
53,815 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2023-02-23 |
4 |
AS |
$68.76 |
$113,179 |
D/D |
(1,646) |
53,883 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• – – |
2023-02-21 |
4 |
D |
$58.50 |
$48,263 |
D/D |
(825) |
55,529 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• – – |
2023-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,886 |
56,354 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2023-01-30 |
4 |
AS |
$52.76 |
$46,587 |
D/D |
(883) |
46,468 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2023-01-27 |
4 |
D |
$52.77 |
$19,367 |
D/D |
(367) |
47,351 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2023-01-23 |
4 |
AS |
$51.58 |
$231,027 |
D/D |
(4,479) |
47,718 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2023-01-20 |
4 |
D |
$52.05 |
$105,818 |
D/D |
(2,033) |
52,197 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Development Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,580 |
54,230 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Exec VP, Program Team Lead |
• • – |
2022-12-22 |
4 |
D |
$51.68 |
$4,600 |
D/D |
(89) |
31,650 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Exec VP, Program Team Lead |
• • – |
2022-04-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,250) |
31,739 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Exec VP, Program Team Lead |
• • – |
2022-01-28 |
4 |
D |
$38.59 |
$16,748 |
D/D |
(434) |
32,989 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Exec VP, Program Team Lead |
• • – |
2022-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
26,051 |
33,423 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Exec VP, Program Team Lead |
• • – |
2021-12-22 |
4 |
D |
$47.82 |
$4,256 |
D/D |
(89) |
7,372 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Exec VP, Program Team Lead |
• • – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
7,461 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Exec VP, Program Team Lead |
• • – |
2021-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
6,211 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Exec VP, Program Team Lead |
• • – |
2020-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,211 |
1,211 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
